-- 
Nasvax Advances Most in Three Months on Trial of Liver Treatment

-- B y   R o n i t   G o o d m a n
-- 
2011-03-21T09:56:24Z

-- http://www.bloomberg.com/news/2011-03-21/nasvax-advances-most-in-three-months-on-trial-of-liver-treatment.html
  Nasvax Ltd. (NSVX)  rose the most in almost
three months after its parent company  Biomedix Incubator Ltd. (BMDX) 
said Nasvaxâ€™s Phase 2a clinical trial of a treatment for fatty
liver was successful.  Nasvax shares climbed as much as 8.9 percent, the biggest
intraday gain since Dec. 27, to 1.63 shekels. They traded 2.3
percent higher at 1.53 shekels as of 11:24 a.m. in Tel Aviv.
Biomedix increased 3.6 percent to 0.607 shekel.  To contact the reporter on this story:
Ronit Goodman in Tel Aviv at 
 rgoodman9@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  